For information, contact:
Stephanie Hoult, (952) 412-7002
PR Account Supervisor, broadhead.
FOR IMMEDIATE RELEASE
High-performing Pigs Start Healthy, End Strong
Disease prevention can make or break a pig’s performance because healthier pigs reach heavier weights.
St. Joseph, Mo. (June 7, 2016) — Producers measure the success of their herds on pig performance – whether that is average daily gain (ADG), feed efficiency, mortality, pigs per litter or other performance statistics. And we know the healthier the pig, the better its lifelong performance.
Boehringer Ingelheim Vetmedica, Inc. (BIVI) knows that preventive health protocols, while a small part of the overall cost, provide a major boost to pig health and performance when raising a healthy pig. With the launch of a new health platform: Start Healthy, End Strong, BIVI has pledged to help farmers succeed in preventing swine diseases by providing the right tools for a healthy start.
Start Healthy, End Strong, was developed on the belief that when you start your pigs off using robust health protocols, they will maximize profits at the market. And disease prevention, through proactive vaccinations versus reactive treatment of diseased pigs, is the key to unlocking their true performance potential.
“With BIVI’s history and expertise in developing new, innovative vaccines, disease prevention in swine is our greatest strength,” says Dr. Kate Christmas, director of swine professional services for BIVI.
BIVI has begun to roll out new resources like SOURCE for PED and PRRS, which is an online, comprehensive library of research-proven swine health solutions. SOURCE continues to expand and offer additional management solutions for both respiratory and enteric diseases. And, through BIVI’s customizable portfolio of respiratory and enteric vaccines it offers one of the most complete vaccine packages in the industry.
“It is part of our belief system that by helping our customers, and partnering with them, by utilizing all of our services – not only our products, but our people, our resources, and our programs – we will ultimately have healthy, uniform pigs in the end,” Dr. Christmas adds.
For more information on Start Healthy, End Strong, visit http://www.bi-vetmedica.com/species/swine.html.
About Boehringer Ingelheim Vetmedica, Inc.
Boehringer Ingelheim Vetmedica, Inc., (BIVI) is the fifth largest animal health company in the U.S. and produces innovative vaccine and pharmaceutical products for the prevention and treatment of diseases in the swine, cattle, equine and companion animal markets. BIVI is the U.S. subsidiary of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other locations in Ames, Fort Dodge and Sioux Center, Iowa.
With more than 3,600 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.13 billion euros in 2014. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11% of net sales of the Animal Health business in R&D.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
©2016 Boehringer Ingelheim Vetmedica, Inc.